AstraZeneca PLC $AZN Shares Sold by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. lowered its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 77.3% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 1,440 shares of the company’s stock after selling 4,910 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in AstraZeneca were worth $101,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of AZN. Goldman Sachs Group Inc. lifted its holdings in shares of AstraZeneca by 30.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock valued at $1,003,124,000 after buying an additional 3,224,251 shares during the period. Valeo Financial Advisors LLC lifted its holdings in shares of AstraZeneca by 14,797.3% in the 2nd quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock valued at $162,306,000 after buying an additional 2,307,047 shares during the period. American Century Companies Inc. lifted its holdings in shares of AstraZeneca by 406.9% in the 1st quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock valued at $148,517,000 after buying an additional 1,621,974 shares during the period. Jennison Associates LLC lifted its holdings in shares of AstraZeneca by 15.2% in the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after buying an additional 1,605,133 shares during the period. Finally, Boston Partners lifted its holdings in shares of AstraZeneca by 35.9% in the 1st quarter. Boston Partners now owns 5,036,645 shares of the company’s stock valued at $368,712,000 after buying an additional 1,329,166 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

NASDAQ AZN opened at $81.72 on Tuesday. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $86.57. The stock has a 50-day moving average of $81.17 and a 200 day moving average of $75.18. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $253.45 billion, a price-to-earnings ratio of 30.72, a PEG ratio of 1.52 and a beta of 0.36.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AZN. Jefferies Financial Group began coverage on AstraZeneca in a report on Monday, October 27th. They issued a “buy” rating for the company. Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday, July 9th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.